30J Stock Overview
A precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
IDEAYA Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.90 |
| 52 Week High | US$39.60 |
| 52 Week Low | US$12.80 |
| Beta | 0.25 |
| 1 Month Change | 28.78% |
| 3 Month Change | -22.17% |
| 1 Year Change | -54.57% |
| 3 Year Change | 130.97% |
| 5 Year Change | 146.90% |
| Change since IPO | 191.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| 30J | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 4.1% | 1.1% | 3.4% |
| 1Y | -54.6% | -14.9% | 15.0% |
Return vs Industry: 30J underperformed the German Biotechs industry which returned -14.9% over the past year.
Return vs Market: 30J underperformed the German Market which returned 14.4% over the past year.
Price Volatility
| 30J volatility | |
|---|---|
| 30J Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 30J's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 30J's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 131 | Yujiro Hata | www.ideayabio.com |
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor.
IDEAYA Biosciences, Inc. Fundamentals Summary
| 30J fundamental statistics | |
|---|---|
| Market cap | €1.58b |
| Earnings (TTM) | -€269.96m |
| Revenue (TTM) | €6.15m |
222.0x
P/S Ratio-5.1x
P/E RatioIs 30J overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 30J income statement (TTM) | |
|---|---|
| Revenue | US$7.00m |
| Cost of Revenue | US$322.75m |
| Gross Profit | -US$315.75m |
| Other Expenses | -US$8.67m |
| Earnings | -US$307.08m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.51 |
| Gross Margin | -4,510.77% |
| Net Profit Margin | -4,386.90% |
| Debt/Equity Ratio | 0% |
How did 30J perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/06 23:18 |
| End of Day Share Price | 2025/05/06 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IDEAYA Biosciences, Inc. is covered by 26 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Zhiqiang Shu | Berenberg |
| Suranjit Mukherjee | BTIG |